Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa
Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose...
Gespeichert in:
| Veröffentlicht in: | AIDS (London) 2005-03, Vol.19 (4), p.441-443 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 443 |
|---|---|
| container_issue | 4 |
| container_start_page | 441 |
| container_title | AIDS (London) |
| container_volume | 19 |
| creator | MOSAM, Anisa CASSOL, Edana LALLOO, Umesh G ESTERHUIZEN, Tonya M COOVADIA, Hoosen M PAGE, Taryn BODASING, Uvani CASSOL, Sharon DAWOOD, Halima FRIEDLAND, Gerald H SCADDEN, David T ABOOBAKER, Jamila JORDAAN, Jacobus P |
| description | Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy. |
| doi_str_mv | 10.1097/01.aids.0000161775.36652.85 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67486885</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67486885</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-d072e456065ab611706b1dd70cc386007c08cb12892d59488fb1137d1219d7c83</originalsourceid><addsrcrecordid>eNqF0U1P3DAQBmALtYIt7V9AkVDpKWEmjj-inhC0FBWJA3DoyZrYjjDKbraeLBL_vllYaY_1xZdnZqT3FeIUoUJozTlgRSlwBfNDjcaoSmqt6sqqA7HAxshSKYMfxAJq3ZatNHAkPjE_z16BtYfiCJVRINt2If5cx1XMyRe0mlKOUx5fUqahiH2fPPnXIq2Ki5ur-5KYR59oiqH4TeuR0zcumLIfl7Q1vOnKe3qiTLPv54X0WXzsaeD4Zfcfi8efPx4uf5W3d9c3lxe3pW-knMoApo6N0qAVdRrRgO4wBAPeS6sBjAfrO6xtWwfVNtb2HaI0AWtsg_FWHouz973rPP7dRJ7cMrGPw0CrOG7YadNYba36L0RjpZK2meH3d-jzyJxj79Y5LSm_OgS3rcABum0Fbl-Be6vAvZ052Z3ZdMsY9rO7zGfwdQeIPQ39HJlPvHfaoJ7zkP8A8BCO3w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17835384</pqid></control><display><type>article</type><title>Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>MOSAM, Anisa ; CASSOL, Edana ; LALLOO, Umesh G ; ESTERHUIZEN, Tonya M ; COOVADIA, Hoosen M ; PAGE, Taryn ; BODASING, Uvani ; CASSOL, Sharon ; DAWOOD, Halima ; FRIEDLAND, Gerald H ; SCADDEN, David T ; ABOOBAKER, Jamila ; JORDAAN, Jacobus P</creator><creatorcontrib>MOSAM, Anisa ; CASSOL, Edana ; LALLOO, Umesh G ; ESTERHUIZEN, Tonya M ; COOVADIA, Hoosen M ; PAGE, Taryn ; BODASING, Uvani ; CASSOL, Sharon ; DAWOOD, Halima ; FRIEDLAND, Gerald H ; SCADDEN, David T ; ABOOBAKER, Jamila ; JORDAAN, Jacobus P</creatorcontrib><description>Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.</description><identifier>ISSN: 0269-9370</identifier><identifier>EISSN: 1473-5571</identifier><identifier>DOI: 10.1097/01.aids.0000161775.36652.85</identifier><identifier>PMID: 15750399</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Acquired Immunodeficiency Syndrome - drug therapy ; Acquired Immunodeficiency Syndrome - immunology ; Acquired Immunodeficiency Syndrome - virology ; Africa South of the Sahara ; AIDS/HIV ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; CD4 Lymphocyte Count ; Dermatology ; Developing Countries ; Drugs, Generic - therapeutic use ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Medical sciences ; Pharmacology. Drug treatments ; Sarcoma, Kaposi - drug therapy ; Treatment Outcome ; Tumors of the skin and soft tissue. Premalignant lesions ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Viral Load</subject><ispartof>AIDS (London), 2005-03, Vol.19 (4), p.441-443</ispartof><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-d072e456065ab611706b1dd70cc386007c08cb12892d59488fb1137d1219d7c83</citedby><cites>FETCH-LOGICAL-c433t-d072e456065ab611706b1dd70cc386007c08cb12892d59488fb1137d1219d7c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16716560$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15750399$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MOSAM, Anisa</creatorcontrib><creatorcontrib>CASSOL, Edana</creatorcontrib><creatorcontrib>LALLOO, Umesh G</creatorcontrib><creatorcontrib>ESTERHUIZEN, Tonya M</creatorcontrib><creatorcontrib>COOVADIA, Hoosen M</creatorcontrib><creatorcontrib>PAGE, Taryn</creatorcontrib><creatorcontrib>BODASING, Uvani</creatorcontrib><creatorcontrib>CASSOL, Sharon</creatorcontrib><creatorcontrib>DAWOOD, Halima</creatorcontrib><creatorcontrib>FRIEDLAND, Gerald H</creatorcontrib><creatorcontrib>SCADDEN, David T</creatorcontrib><creatorcontrib>ABOOBAKER, Jamila</creatorcontrib><creatorcontrib>JORDAAN, Jacobus P</creatorcontrib><title>Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa</title><title>AIDS (London)</title><addtitle>AIDS</addtitle><description>Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.</description><subject>Acquired Immunodeficiency Syndrome - drug therapy</subject><subject>Acquired Immunodeficiency Syndrome - immunology</subject><subject>Acquired Immunodeficiency Syndrome - virology</subject><subject>Africa South of the Sahara</subject><subject>AIDS/HIV</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>CD4 Lymphocyte Count</subject><subject>Dermatology</subject><subject>Developing Countries</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Sarcoma, Kaposi - drug therapy</subject><subject>Treatment Outcome</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><subject>Viral Load</subject><issn>0269-9370</issn><issn>1473-5571</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U1P3DAQBmALtYIt7V9AkVDpKWEmjj-inhC0FBWJA3DoyZrYjjDKbraeLBL_vllYaY_1xZdnZqT3FeIUoUJozTlgRSlwBfNDjcaoSmqt6sqqA7HAxshSKYMfxAJq3ZatNHAkPjE_z16BtYfiCJVRINt2If5cx1XMyRe0mlKOUx5fUqahiH2fPPnXIq2Ki5ur-5KYR59oiqH4TeuR0zcumLIfl7Q1vOnKe3qiTLPv54X0WXzsaeD4Zfcfi8efPx4uf5W3d9c3lxe3pW-knMoApo6N0qAVdRrRgO4wBAPeS6sBjAfrO6xtWwfVNtb2HaI0AWtsg_FWHouz973rPP7dRJ7cMrGPw0CrOG7YadNYba36L0RjpZK2meH3d-jzyJxj79Y5LSm_OgS3rcABum0Fbl-Be6vAvZ052Z3ZdMsY9rO7zGfwdQeIPQ39HJlPvHfaoJ7zkP8A8BCO3w</recordid><startdate>20050304</startdate><enddate>20050304</enddate><creator>MOSAM, Anisa</creator><creator>CASSOL, Edana</creator><creator>LALLOO, Umesh G</creator><creator>ESTERHUIZEN, Tonya M</creator><creator>COOVADIA, Hoosen M</creator><creator>PAGE, Taryn</creator><creator>BODASING, Uvani</creator><creator>CASSOL, Sharon</creator><creator>DAWOOD, Halima</creator><creator>FRIEDLAND, Gerald H</creator><creator>SCADDEN, David T</creator><creator>ABOOBAKER, Jamila</creator><creator>JORDAAN, Jacobus P</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20050304</creationdate><title>Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa</title><author>MOSAM, Anisa ; CASSOL, Edana ; LALLOO, Umesh G ; ESTERHUIZEN, Tonya M ; COOVADIA, Hoosen M ; PAGE, Taryn ; BODASING, Uvani ; CASSOL, Sharon ; DAWOOD, Halima ; FRIEDLAND, Gerald H ; SCADDEN, David T ; ABOOBAKER, Jamila ; JORDAAN, Jacobus P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-d072e456065ab611706b1dd70cc386007c08cb12892d59488fb1137d1219d7c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acquired Immunodeficiency Syndrome - drug therapy</topic><topic>Acquired Immunodeficiency Syndrome - immunology</topic><topic>Acquired Immunodeficiency Syndrome - virology</topic><topic>Africa South of the Sahara</topic><topic>AIDS/HIV</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>CD4 Lymphocyte Count</topic><topic>Dermatology</topic><topic>Developing Countries</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Sarcoma, Kaposi - drug therapy</topic><topic>Treatment Outcome</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><topic>Viral Load</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MOSAM, Anisa</creatorcontrib><creatorcontrib>CASSOL, Edana</creatorcontrib><creatorcontrib>LALLOO, Umesh G</creatorcontrib><creatorcontrib>ESTERHUIZEN, Tonya M</creatorcontrib><creatorcontrib>COOVADIA, Hoosen M</creatorcontrib><creatorcontrib>PAGE, Taryn</creatorcontrib><creatorcontrib>BODASING, Uvani</creatorcontrib><creatorcontrib>CASSOL, Sharon</creatorcontrib><creatorcontrib>DAWOOD, Halima</creatorcontrib><creatorcontrib>FRIEDLAND, Gerald H</creatorcontrib><creatorcontrib>SCADDEN, David T</creatorcontrib><creatorcontrib>ABOOBAKER, Jamila</creatorcontrib><creatorcontrib>JORDAAN, Jacobus P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>AIDS (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MOSAM, Anisa</au><au>CASSOL, Edana</au><au>LALLOO, Umesh G</au><au>ESTERHUIZEN, Tonya M</au><au>COOVADIA, Hoosen M</au><au>PAGE, Taryn</au><au>BODASING, Uvani</au><au>CASSOL, Sharon</au><au>DAWOOD, Halima</au><au>FRIEDLAND, Gerald H</au><au>SCADDEN, David T</au><au>ABOOBAKER, Jamila</au><au>JORDAAN, Jacobus P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa</atitle><jtitle>AIDS (London)</jtitle><addtitle>AIDS</addtitle><date>2005-03-04</date><risdate>2005</risdate><volume>19</volume><issue>4</issue><spage>441</spage><epage>443</epage><pages>441-443</pages><issn>0269-9370</issn><eissn>1473-5571</eissn><abstract>Generic antiretroviral drugs are pivotal in the implementation of WHO's '3 by 5' programme. However, clinical experience with generics in sub-Saharan Africa is insufficiently documented. We report on 50 patients with HIV-associated Kaposi's sarcoma treated with generic fixed-dose highly active antiretroviral therapy. At 52 weeks, 74% achieved an undetectable viral load of < 50 copies/ml, 86% achieved < 400 copies/ml, and a 3.1 log10 decline from baseline. Side-effects were minimal. The outcomes support the use of generic antiretroviral therapy.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>15750399</pmid><doi>10.1097/01.aids.0000161775.36652.85</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-9370 |
| ispartof | AIDS (London), 2005-03, Vol.19 (4), p.441-443 |
| issn | 0269-9370 1473-5571 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67486885 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete |
| subjects | Acquired Immunodeficiency Syndrome - drug therapy Acquired Immunodeficiency Syndrome - immunology Acquired Immunodeficiency Syndrome - virology Africa South of the Sahara AIDS/HIV Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Dermatology Developing Countries Drugs, Generic - therapeutic use Human immunodeficiency virus Human viral diseases Humans Infectious diseases Medical sciences Pharmacology. Drug treatments Sarcoma, Kaposi - drug therapy Treatment Outcome Tumors of the skin and soft tissue. Premalignant lesions Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids Viral Load |
| title | Generic antiretroviral efficacy in AIDS-associated Kaposi's sarcoma in sub-Saharan Africa |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T11%3A27%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generic%20antiretroviral%20efficacy%20in%20AIDS-associated%20Kaposi's%20sarcoma%20in%20sub-Saharan%20Africa&rft.jtitle=AIDS%20(London)&rft.au=MOSAM,%20Anisa&rft.date=2005-03-04&rft.volume=19&rft.issue=4&rft.spage=441&rft.epage=443&rft.pages=441-443&rft.issn=0269-9370&rft.eissn=1473-5571&rft_id=info:doi/10.1097/01.aids.0000161775.36652.85&rft_dat=%3Cproquest_cross%3E67486885%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17835384&rft_id=info:pmid/15750399&rfr_iscdi=true |